Company Overview and News

0
Peregrine Diamonds Ltd. to be Acquired by De Beers Canada Inc. for $0.24 per Share in Cash

8h globenewswire
VANCOUVER, British Columbia, July 19, 2018 (GLOBE NEWSWIRE) -- Peregrine Diamonds Ltd. (TSX:PGD) (“Peregrine” or “the Company”) is pleased to announce that it has entered into an arrangement agreement (the “Arrangement Agreement”) with De Beers Canada Inc. (“De Beers”) under which De Beers will acquire all of the Company’s outstanding common shares for $0.24 per share in cash or a total equity value of approximately $107 million pursuant to a plan of arrangement (the “Arrangement”) under the Canada Business Corporations Act.
PGD AAUKF PGDIF MALRY MDM AAL MALRF MIN NGLOY MPVD

0
Trevali Reports Preliminary Q2-2018 Production of 104 Million Payable Pounds of Zinc and Operating Costs of US$58 Per Tonne

2018-07-18 globenewswire
VANCOUVER, British Columbia, July 18, 2018 (GLOBE NEWSWIRE) -- Trevali Mining Corporation (“Trevali” or the “Company”) (TSX:TV) (OTCQX:TREVF) (Frankfurt:4TI) reports preliminary consolidated second quarter 2018 (“Q2-2018”) production of 103.9 million payable pounds of zinc, 10.5 million payable pounds of lead and 337,801 payable ounces of silver (Table 1). The Company remains firmly on track with its 2018 consolidated annual production guidance of 400-427 million payable pounds of zinc.
MALRY MALRF MIN TREVF TV

0
Monument Announces NI43-101 Mineral Resource Update at the Burnakura Property, Western Australia

2018-07-18 globenewswire
VANCOUVER, British Columbia, July 18, 2018 (GLOBE NEWSWIRE) -- Monument Mining Limited (TSXV:MMY) (FSE:D7Q1) ("Monument" or the "Company") is pleased to announce a Mineral Resource estimate update for the Burnakura property of the Murchison Gold Project in Western Australia, which has been included in “NI 43-101 Technical Report: Updated Mineral Resources, Burnakura Gold Project, Western Australia, Australia” (the “NI43-101 Technical Report”) dated July 17, 2018 and Sedar filed on July 18, 2018 under www.
MMTMF MMY MALRY MALRF MIN

4
Winter Drilling Strengthens Model for Large-Scale Intrusive Hosted Gold System at Éléonore South

2018-07-18 globenewswire
TORONTO, July 18, 2018 (GLOBE NEWSWIRE) -- Eastmain Resources Inc. (“Eastmain” or the “Company”) (TSX:ER) (OTCQX:EARNF) is pleased to announce the receipt of assay results from 32 drill holes totalling 5,449 m completed during the winter drilling campaign at the Éléonore South Joint Venture (ESJV) Property (Eastmain-Goldcorp-Azimut). This phase completes the H2/2017-H1/2018 diamond drilling program of 50 holes for a total of 9,892 m.
EANRF ER AZMTF G MALRY MALRF GG MIN AZM

0
ScoZinc Completes $500,000 Non-Brokered Private Placement With MRI Trading AG

2018-07-18 globenewswire
COOKS BROOK, Nova Scotia, July 18, 2018 (GLOBE NEWSWIRE) -- ScoZinc Mining Ltd. (TSX-V:SZM) (“ScoZinc” or the “Company”) is pleased to announce that it has completed a non-brokered private placement financing for aggregate gross proceeds of C$500,000 (the "Offering") with MRI Trading AG (“MRI”). The Offering consisted of the sale of 500,000 units ( the “Units”) at a price of C$1.00 per Unit, with each Unit comprised of one common share (the “Common Shares”) and one common share purchase warrant exercisable for two years at a price of $1.
MALRY MALRF SZM MIN

0
Hexagon Resources achieves positive lithium battery test results

2018-07-17 proactiveinvestors.com.au
Hexagon Resources Ltd (ASX:HXG) has revealed impressive initial cell cycling test work results using purified, uncoated spherical graphite sourced from its McIntosh project in Western Australia.
HXG MALRY MALRF MIN

0
Mustang Resources to merge ruby assets with Fura Gems for $10m

2018-07-17 australianmining.com.au
Mustang Resources has entered into a merger agreement with Toronto- and Dubai-based Fura Gems, a new gemstone mining company with emerald and ruby assets in Mozambique and Colombia.
MUS FUGMF MALRY MALRF MIN

0
Equinox Gold Announces Results of Castle Mountain Prefeasibility Study

2018-07-16 globenewswire
VANCOUVER, British Columbia, July 16, 2018 (GLOBE NEWSWIRE) -- Equinox Gold Corp. (TSX-V:EQX) (OTC:EQXGF) (“Equinox Gold” or the “Company”) is pleased to announce the results of the prefeasibility study (“PFS”) for its 100% owned Castle Mountain Gold Mine (“Castle Mountain” or the “Project”) located in California, USA. The PFS contemplates a low-cost heap leach gold mine with 3.6 million ounces (“oz”) of gold reserves that will produce 2.
MALRY MALRF EQXGF MIN

7
Sandstorm Gold Royalties Provides Corporate and Asset Updates

2018-07-16 accesswire
VANCOUVER, BC / ACCESSWIRE / July 16, 2018 / Sandstorm Gold Ltd. ("Sandstorm Gold Royalties,'' "Sandstorm" or the "Company") (NYSE American: SAND; TSX: SSL) is pleased to provide an update related to share repurchases under the Company's Normal Course Issuer Bid ("NCIB"), recent developments from the Company's royalty portfolio, as well as the acquisition of eight royalties on exploration-staged properties.
YRI KGI.DB MALRY MEAOF AU NXXGD MIN AULGF NXXGF AUY EDVVF AGG KL EDV SSL SAND SDDXF KGI NXS KGI.DB.A EDVMF SNXZF EQXGF EVR MALRF ERDCF

0
Aura Minerals Announces the Results of the NI 43-101 Feasibility Study for the Restart of Operations at the Aranzazu Mine in Zacatecas, Mexico

2018-07-16 globenewswire
BRITISH VIRGIN ISLANDS, Caribbean, July 16, 2018 (GLOBE NEWSWIRE) -- Aura Minerals Inc. (TSX:ORA) (“Aura”, the “Company”) is pleased to announce results of the positive National Instrument 43-101 Feasibility Study (“FS”) for the restart of operations at Aura’s wholly owned Aranzazu Mine (“Aranzazu”, the “Project”) in Zacatecas State, Mexico. The FS was prepared by Aura in collaboration with other external consultants and specialists in different areas such as geology, mining, geotechnical, infrastructure, environment and mineral processing.
ORA ARMZF MALRY MALRF MIN

0
Novo Exercises Right to Purchase Half of Comet Well Royalty

2018-07-16 globenewswire
VANCOUVER, British Columbia, July 16, 2018 (GLOBE NEWSWIRE) -- Novo Resources Corp. (“Novo” or the “Company”) (TSX-V:NVO) (OTCQX:NSRPF) is pleased to announce that it has exercised its right of first refusal (the “ROFR”) to purchase one-half of a 1% net smelter returns royalty (the “NSR”) on the Company’s Comet Well property in the Karratha region of Western Australia (the “Acquisition”). The Company is exercising its ROFR and matching the terms of an offer made by International Prospect Ventures Ltd.
NSRPF NVO MALRY MALRF MIN

2
Cardinal Makes New Gold Discovery at Ndongo

2018-07-16 globenewswire
TORONTO, July 16, 2018 (GLOBE NEWSWIRE) -- Cardinal Resources Limited (ASX:CDV) (TSX:CDV) (“Cardinal” or “the Company”) is pleased to announce that it has intersected further gold at a new discovery named Ndongo East on its 100% owned Ndongo License, located approximately 15 km north of the Company’s flagship Namdini Gold Project which has a 6.5 Moz Indicated Mineral Resource (Figure 1).
KGC MALRY K MALRF CDV MIN CDV CDNL

0
'Fair and reasonable': Rinehart bid for Atlas receives boost

2018-07-16 theage.com.au
The $390 million offer by the Gina Rinehart camp for Atlas Iron has been declared “fair and reasonable” in an independent expert’s report examining the offer for the loss-making junior miner.
AGO FSUMF ATLGF AGODY MALRY FMG MALRF MIN FSUGY

0
'Fair and reasonable': Rinehart bid for Atlas receives boost

2018-07-16 smh.com.au
The $390 million offer by the Gina Rinehart camp for Atlas Iron has been declared “fair and reasonable” in an independent expert’s report examining the offer for the loss-making junior miner.
AGO FSUMF ATLGF AGODY MALRY FMG MALRF MIN FSUGY

0
Atlas Iron urges investors to accept Hancock takeover

2018-07-16 australianmining.com.au
Atlas Iron’s directors have unanimously recommended shareholders accept Hancock Prospecting subsidiary Redstone Corporation’s $390 million takeover offer in a company target statement.
AGO ATLGF AGODY MALRY MALRF MIN

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: Q60976109